Newsletters


Filter by volume

Agenus on Twitter

Today, we took another step in advancing our immuno-oncology therapies to cancer patients. We announced that the first patient has been dosed with AGEN1777, our first-in-class #TIGIT bispecific licensed to @bmsnews, triggering a $20M milestone payment. investor.agenusbio.com/news-releases/…

WHO recommends broader use of the world’s first malaria vaccine, containing Agenus’ QS-21 Stimulon. Read today’s story from @BosBizJournal. @garo_armen bizjournals.com/boston/news/20…

Yesterday, @WHO rec. widespread use of the 1st malaria vaccine to young children in sub-Saharan Africa —what made the news more interesting was the fact that it was a 27-yr old biotech in Lexington that made the vaccine possible. @garo_armen @Agenus_Bio bit.ly/2YvXHgk Retweeted by Agenus Inc. ($AGEN)

Live from #BioFuture21, @jbuell01 discusses the future of cancer treatment and emerging areas of innovation in oncology

test Twitter Media - Live from #BioFuture21, @jbuell01 discusses the future of cancer treatment and emerging areas of innovation in oncology https://t.co/CmNwfKJAB8

Targeting ILT-4 with $AGEN discovered antibody, MK-4830, may increase the anti-tumor activity of pembrolizumab even in tumors with low levels of T-cell inflammation. Publication in Clinical Cancer Research discusses potential of ILT-4 blockade to abrogate PD-1/PD-L1 resistance twitter.com/CCR_AACR/statu…

Tune in today, at 1:30pm EST, to hear @jbuell01 speak at the BioFuture 2021 panel, “Next Gen Oncology Therapeutics: Changing the Cancer Landscape.” biofuture.com/biofuture-regi…

test Twitter Media - Tune in today, at 1:30pm EST, to hear @jbuell01 speak at the BioFuture 2021 panel, “Next Gen Oncology Therapeutics: Changing the Cancer Landscape.”

https://t.co/qFVR2GlF0m https://t.co/DrwguvMfAQ

Oh the talent density @Agenus_Bio and @MiNK_iNKT! twitter.com/jbuell01/statu…

September is #GynecologicCancerAwarenessMonth and we at $AGEN are committed to fighting gynecologic cancers by advancing important therapeutic options for patients, spreading awareness, and encouraging education.

Bal/Zal Doubles Responses Compared to Currently Available Therapies at #ESMO21 Data demonstrate the power of our combo approach to improve patient outcomes and address difficult tumors, while remaining well-tolerated for patients. Today's Newsletter: agenusbio.com/newsletters/ag…

Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer onclive.com/view/balstilim… via @onclive Retweeted by Agenus Inc. ($AGEN)

Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer @myESMO #ESMO21 @OSUCCC_James #gyncsm onclive.com/view/balstilim… Retweeted by Agenus Inc. ($AGEN)

Results of a phase 2 study demonstrate that the anti-programmed death-1 (PD-1) antibody balstilimab from Agenus Inc. provides meaningful and durable clinical activity in patients with previously treated, recurrent/metastatic cervical cancer. bit.ly/3tHtaaw Retweeted by Agenus Inc. ($AGEN)

“Building Biotech: Masterclass w/ Jennifer Buell, Agenus COO” with @jbuell01 @Agenus_Bio, @Jack_O_Meara, @nabsicle, and DNA Tie Club. Sunday, Sep 19 at 10:00 AM PDT in @clubhouse! clubhouse.com/event/mgllK8Ap Retweeted by Agenus Inc. ($AGEN)

"Agenus congratulates @Ginkgo on their trading debut on @NYSE. We are excited to continue our collaboration with Ginkgo to revolutionize vaccines through our subsidiary @saponiQx" -@garo_armen twitter.com/Ginkgo/status/…

Bal/Zal combination data presented at #ESMO21 shows improved responses across histology subgroups, and anti-PD-1 alone. Further data to be presented on Sept. 19th. investor.agenusbio.com/news-releases/…

$AGEN combination of balstilimab plus zalifrelimab doubles responses in 2L cervical cancer in data to be presented at ESMO investor.agenusbio.com/index.php/news…

ICYMI: Follow the link to join, @jbuell01, this afternoon, at 4:20 EDT, for our presentation at the Baird 2021 Global Healthcare Conference. investor.agenusbio.com/events/event-d…

SaponiQx is proud to partner with @Ginkgo Bioworks to develop the next generation of saponin adjuvants. Pairing SaponiQx’s unique expertise in saponins and Gingko Bioworks’ Foundry technology will provide a platform for innovation! #Biotechnology #agenus investor.agenusbio.com/news-releases/… Retweeted by Agenus Inc. ($AGEN)